| Literature DB >> 30429127 |
Cara B Ebbeling1,2, Henry A Feldman2,3, Gloria L Klein1, Julia M W Wong1,2, Lisa Bielak1, Sarah K Steltz1, Patricia K Luoto4, Robert R Wolfe5, William W Wong6, David S Ludwig7,2.
Abstract
OBJECTIVE: To determine the effects of diets varying in carbohydrate to fat ratio on total energy expenditure.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30429127 PMCID: PMC6233655 DOI: 10.1136/bmj.k4583
Source DB: PubMed Journal: BMJ ISSN: 0959-8138
Fig 1Study design
Dietary energy and macronutrient composition for test diets, calculated daily averages (for a 2000 kcal target)*
| Variables | Carbohydrate content | ||
|---|---|---|---|
| High | Moderate | Low | |
| Energy (kcal) | 2001 | 2001 | 2001 |
| Carbohydrate (g) | 305 | 205 | 105 |
| Carbohydrate (%)† | 59.2 | 39.7 | 20.3 |
| Glycemic index‡ | 49 | 46 | 30 |
| Glycemic load (g)‡ | 135 | 80 | 28 |
| Fat (g) | 48 | 92 | 137 |
| Fat (%)† | 20.9 | 40.1 | 59.6 |
| Saturated fat (%)§ | 5.9 | 13.7 | 20.9 |
| Monounsaturated fat (%)§ | 8.2 | 15.9 | 25.1 |
| Polyunsaturated fat (%)§ | 5.3 | 8.6 | 11.3 |
| Protein (g) | 102 | 104 | 103 |
| Protein (%)† | 19.9 | 20.2 | 20.1 |
| Fiber (g) | 33 | 28 | 22 |
| Food quotient¶ | 0.90 | 0.85 | 0.79 |
Values were calculated using Food Processor Nutrition Analysis Software (ESHA Research, Salem, OR).
Per cent of energy from macronutrients takes into account digestibility for some foods.
Glycemic index for each day was calculated by summing the weighted values for each food item: Σ(glycemic index for food item×proportion of total net carbohydrate contributed by item).26 Glycemic load was calculated as the product of the glycemic index and net carbohydrate for the day: (glycemic index/100)×net carbohydrate.27
Per cent of total energy. The target for saturated fat was 35% of total fat (equating to 7%, 14%, and 21% of total energy for high, moderate, and low carbohydrate diets, respectively). The remainder of the total fat target (20%, 40%, and 60% of total energy) was distributed between monounsaturated and polyunsaturated fat. The sum of saturated, monounsaturated, and polyunsaturated fat does not equal total fat because data on fat type were missing for some foods.
Food quotient (FQ) calculated using the equation of Black et al.28 FQ=(carbohydrate(%)×1.00)+(fat(%)×0.71)+(protein(%)×0.81).
Fig 2Participant flow (see supplementary figure for details of exclusions)
Pre-weight loss characteristics of 164 study participants by diet group. Values are means (standard deviations) unless stated otherwise
| Characteristics | Carbohydrate content | ||
|---|---|---|---|
| High (n=54) | Moderate (n=53) | Low (n=57) | |
| Men | 12 (22) | 17 (32) | 20 (35) |
| Women | 42 (78) | 36 (68) | 37 (65) |
| Hispanic ethnicity,* No (%) | 8 (15) | 7 (13) | 10 (18) |
| Race, No (%)*: | |||
| White | 44 (81) | 41 (77) | 43 (75) |
| Black | 4 (7) | 7 (13) | 6 (11) |
| Asian | 2 (4) | 2 (4) | 1 (2) |
| Unknown/other | 4 (7) | 3 (6) | 7 (12) |
| Age (years) | 39.8 (15.1) | 37.3 (14.9) | 37.1 (13.3) |
| Weight (kg) | 88.4 (16.6) | 94.8 (19.7) | 91.2 (17.9) |
| Weight loss (% of pre-weight loss) | 10.6 (1.7) | 10.5 (1.8) | 10.3 (1.6) |
| Height (cm) | 166.7 (9.0) | 167.9 (11.2) | 168.5 (9.8) |
| Body mass index | 31.7 (4.3) | 33.5 (5.3) | 32.0 (4.8) |
| Total energy expenditure (kcal/d) | 2915 (686) | 3030 (788) | 3110 (680) |
| Resting energy expenditure (kcal/d) | 1654 (318) | 1751 (387) | 1695 (331) |
| Physical activity: | |||
| Total physical activity (counts/d, 000s)† | 510.0 (172.1) | 509.1 (146.4) | 525.2 (182.4) |
| MVPA (min/d)‡ | 26.4 (19.4) | 27.7 (19.5) | 29.7 (19.8) |
| Sedentary time (min/d)§ | 567.2 (91.0) | 591.8 (105.4) | 566.1 (97.1) |
| Skeletal muscle work efficiency at 10 W (%) | 11.1 (2.5) | 10.3 (2.6) | 11.1 (3.6) |
| Ghrelin level (pg/mL) | 648.6 (293.7) | 530.0 (281.0) | 558.2 (288.3) |
| Leptin level (ng/mL) | 31.3 (16.4) | 30.6 (19.0) | 27.5 (16.4) |
| Body composition: | |||
| Body fat mass (% of total mass) | 41.4 (5.5) | 41.1 (7.3) | 40.0 (5.8) |
| Lean body mass (% of total mass)¶ | 56.0 (5.3) | 56.3 (7.0) | 57.3 (5.6) |
| Abnormal fasting blood glucose, No (%)** | 18 (33) | 19 (36) | 16 (28) |
| Fasting glucose (mg/dL) | 97 (9) | 97 (9) | 99 (11) |
| Fasting insulin (μIU/mL) | 13.9 (6.8) | 15.6 (10.3) | 19.7 (21.1) |
MVPA=moderate to vigorous physical activity.
Determined by self report using fixed categories. White: a person having origins in any of the original peoples of Europe, the Middle East, or North Africa. Black: a person having origins in any of the black racial groups of Africa. Asian: a person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent.
Quantified based on triaxial counts, representing a composite vector magnitude of three orthogonal planes (vertical, anteroposterior, mediolateral).43 Average accelerometer wear time was mean 14.8 (SD 1.3) hours per day.
Quantified using vertical axis count thresholds of Troiano et al.44
Defined as <100 counts per minute for vertical axis counts.43
Lean body mass does not include bone mineral content.
Fasting blood glucose ≥100 mg/dL.
Fig 3Change in total energy expenditure, the primary outcome, in intention-to-treat (top) and per protocol (bottom) analyses. Data are shown as mean change from start of test phase, with whiskers representing 1 standard error above and below the mean. P tests uniformity across diet groups for average of changes at midpoint and end of test phase
Primary and secondary outcomes involving energy expenditure, physical activity, and metabolic hormones*
| Variables | No | Mean (SD) pre-randomization start of trial | Change: average(midpoint of test phase, end of test phase)−start of trial | ||
|---|---|---|---|---|---|
| Mean (95% CI) | P value between groups | Trend estimate (95% CI)† | |||
|
| |||||
| Intention-to-treat: | |||||
| High | 54 | 2640 (62) | −19 (−104 to 66) | 0.002 | 52 (23 to 82) |
| Moderate | 52 | 2504 (65) | 71 (−12 to 155) | ||
| Low | 56 | 2713 (64) | 190 (109 to 270) | ||
| Per protocol: | |||||
| High | 38 | 2711 (77) | −102 (−201 to −2) | <0.001 | 69 (36 to 103) |
| Moderate | 39 | 2577 (72) | 29 (−64 to 123) | ||
| Low | 43 | 2758 (70) | 176 (87 to 265) | ||
|
| |||||
| Intention-to-treat: | |||||
| High | 54 | 1603 (24) | 34 (10 to 57) | 0.47 | 5 (−3 to 13) |
| Moderate | 51 | 1576 (25) | 46 (23 to 69) | ||
| Low | 56 | 1615 (24) | 54 (32 to 76) | ||
| Per protocol: | |||||
| High | 38 | 1601 (28) | 20 (−8 to 48) | 0.18 | 8 (−1 to 18) |
| Moderate | 38 | 1597 (27) | 28 (2 to 54) | ||
| Low | 43 | 1608 (26) | 53 (28 to 78) | ||
|
| |||||
| Intention-to-treat: | |||||
| High | 54 | 476.6 (23.3) | −26.3 (−52.0 to −0.6) | 0.13 | 4.8 (−3.9 to 13.6) |
| Moderate | 52 | 463.8 (24.9) | −42.4 (−67.7 to −17.1) | ||
| Low | 55 | 495.8 (23.9) | −6.9 (−31.0 to 17.1) | ||
| Per protocol: | |||||
| High | 38 | 493.2 (28.8) | −29.1 (−59.0 to 0.7) | 0.17 | 4.4 (−5.6 to 14.3) |
| Moderate | 39 | 481.3 (27.0) | −48.3 (−76.3 to −20.3) | ||
| Low | 42 | 521.3 (26.3) | −11.6 (−38.2 to 14.9) | ||
|
| |||||
| Intention-to-treat: | |||||
| High | 54 | 31.6 (2.6) | −3.6 (−6.3 to −0.9) | 0.09 | 0.7 (−0.2 to 1.6) |
| Moderate | 52 | 31.3 (2.7) | −4.8 (−7.5 to −2.1) | ||
| Low | 55 | 30.0 (2.6) | −0.9 (−3.4 to 1.6) | ||
| Per protocol: | |||||
| High | 38 | 33.4 (3.0) | −4.3 (−7.4 to −1.1) | 0.06 | 0.9 (−0.1 to 2.0) |
| Moderate | 39 | 33.0 (2.8) | −5.2 (−8.1 to −2.2) | ||
| Low | 42 | 32.2 (2.8) | −0.5 (−3.3 to 2.3) | ||
|
| |||||
| Intention-to-treat: | |||||
| High | 54 | 592.1 (14.2) | 8.6 (−7.7 to 25.0) | 0.12 | −2.7 (−8.3 to 2.9) |
| Moderate | 52 | 604.7 (14.8) | 20.9 (4.8 to 37.0) | ||
| Low | 55 | 597.0 (14.6) | −2.3 (−17.6 to 13.0) | ||
| Per protocol: | |||||
| High | 38 | 593.6 (17.2) | 2.1 (−17.7 to 22.0) | 0.31 | 0.9 (−5.8 to 7.5) |
| Moderate | 39 | 611.0 (16.1) | 21.4 (2.8 to 40.0) | ||
| Low | 42 | 589.4 (15.7) | 5.6 (−12.0 to 23.1) | ||
|
| |||||
| Intention-to-treat: | |||||
| High | 53 | 12.2 (0.3) | −0.1 (−0.8 to 0.5) | 0.66 | 0.1 (−0.1 to 0.3) |
| Moderate | 51 | 11.7 (0.4) | −0.0 (−0.6 to 0.6) | ||
| Low | 55 | 12.2 (0.3) | 0.3 (−0.3 to 0.9) | ||
| Per protocol: | |||||
| High | 38 | 12.1 (0.4) | −0.1 (−0.9 to 0.6) | 0.46 | 0.1 (−0.1 to 0.4) |
| Moderate | 38 | 11.9 (0.4) | −0.0 (−0.7 to 0.6) | ||
| Low | 42 | 12.2 (0.4) | 0.5 (−0.2 to 1.1) | ||
|
| |||||
| Intention-to-treat: | |||||
| High | 54 | 693.2 (51.4) | -4.9 (−8.4 to −1.2) | 0.02 | −1.9 (−3.2 to −0.6) |
| Moderate | 51 | 640.1 (49.9) | −8.7 (−12.0 to −5.3) | ||
| Low | 56 | 598.2 (45.4) | −11.8 (−14.8 to −8.6) | ||
| Per protocol: | |||||
| High | 38 | 689.5 (63.0) | −5.9 (−10.1 to −1.5) | 0.02 | −2.1 (−3.7 to −0.6) |
| Moderate | 38 | 620.6 (52.8) | −8.0 (−11.8 to −4.0) | ||
| Low | 43 | 603.0 (49.0) | −13.5 (−16.9 to −10.0) | ||
|
| |||||
| Intention-to-treat: | |||||
| High | 54 | 10.9 (1.6) | 34.2 (21.8 to 47.7) | 0.07 | −3.3 (−6.8 to 0.1) |
| Moderate | 51 | 9.8 (1.5) | 34.8 (22.6 to 48.2) | ||
| Low | 56 | 9.6 (1.4) | 17.9 (7.7 to 29.1) | ||
| Per protocol: | |||||
| High | 38 | 11.8 (2.2) | 47.6 (33.9 to 62.8) | 0.009 | −4.9 (−8.4 to −1.5) |
| Moderate | 38 | 8.6 (1.5) | 42.0 (29.4 to 55.8) | ||
| Low | 43 | 9.0 (1.5) | 21.9 (11.7 to 33.0) | ||
Means and changes were constructed and compared from repeated measures analysis of variance, unadjusted except for structural design variables (study site, cohort, enrolment wave).
Linear trend across diet groups for every 10% decrease in the contribution of carbohydrate to total energy intake. Estimates are equivalent to comparing the high with low carbohydrate diet, divided by 4 (with these two diet groups differing in carbohydrate by 40%).
Quantified based on triaxial counts, representing a composite vector magnitude of three orthogonal planes (vertical, anteroposterior, mediolateral).43 Average accelerometer wear time was mean 14.9 (SD 1.2) hours per day.
Quantified using vertical axis count thresholds of Troiano et al.44
Defined as <100 counts per minute for vertical axis counts.43
Efficiency is expressed as percentage ratio of power generated (with conversion of Watts to kcal/min using a factor of 0.01433) to energy expenditure above resting (kcal/min).45 46 Data not collected at midpoint of test phase. Change: end of test phase−start of trial. There were no significant group effects at 10 W (presented here), 25 W, and 50 W.
Hormone levels were log transformed for analysis. For reporting, the adjusted mean and standard error were retransformed to the original units (exp(mean log)±exp(mean log)×(exp(SE log)–1)), and changes were expressed in percentage units (100%×(exp(change in log)–1)).
Fig 4Effect modification by pre-weight loss insulin secretion (insulin concentration 30 minutes after oral glucose) in intention-to-treat and per protocol analyses. Pre-weight loss body weight differed by third (first third, 83.8 kg; second third, 92.8 kg; third third 98.4 kg, P<0.001 in the intention-to-treat analysis). Change in body weight during the test phase did not differ by third (P=0.08) or across diet groups (P=0.43)
Fig 5Biomeasures of compliance in intention-to-treat and per protocol analyses. Measures include 1,5-anhydroglucitol (upper), mean pre-weight loss value 17 μg/mL; triglycerides (middle), mean pre-weight loss value 78 mg/dL (retransformed); and high density lipoprotein cholesterol (lower), mean pre-weight loss value 48 mg/dL. Data are shown as mean change from start of test phase, with whiskers representing 1 standard error above and below the mean. P tests uniformity across diet groups for average of changes at midpoint and end of test phase. Left, intention-to-treat analysis; right, per-protocol analysis